Key facts
- It has raised $3.3M; the latest was Seed Round ($3.3M) in Jan 2025.
- Notable investors include Nissay Capital, San-Ai Corporation, Summit Pharmaceuticals, Waseda University Ventures.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for EVerMed (Drug Discovery)
- ·The full record, as it builds
Funding rounds
No funding rounds for EVerMed (Drug Discovery) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About EVerMed (Drug Discovery)
Operator of a biotechnology company intended to realize everlasting medical treatment through the therapeutic use of extracellular vesicles. The company focuses on the use of EVs, a natural homeostatic mechanism in the human body, and tries to create new treatments that address the root causes of diseases, enabling medical professionals to provide treatment for intractable respiratory diseases using extracellular vesicles.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2024
- Website
- evermed.jp/
- Ownership
- Privately Held (backing)
EVerMed (Drug Discovery) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in EVerMed (Drug Discovery) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on EVerMed (Drug Discovery) in its N-PORT filings yet. We sweep new filings monthly.